T. Schuster

Development of AEZS-115 (ZEN-019) by optimization of structurally unique, orally active, peptidomimetic GnRH antagonists.

M. Teifel, K. Paulini, S. Baasner, 2009, Advances in experimental medicine and biology.

Potential of surfactant‐coated nanoparticles to improve brain delivery of arylsulfatase A

J. Kreuter, V. Gieselmann, S. Gelperina, 2017, Journal of controlled release : official journal of the Controlled Release Society.

A Convenient Synthesis of Novel2,8-Disubstituted Pyrido[3,4-b]pyrazines PossessingBiological Activity

E. Günther, M. Gerlach, T. Schuster, 2012 .

Discovery of 7‐Aryl‐Substituted (1,5‐Naphthyridin‐4‐yl)ureas as Aurora Kinase Inhibitors

M. Teifel, E. Günther, M. Gerlach, 2014, ChemMedChem.

Preparation of Novel 2,3,8-TrisubstitutedPyrido[3,4-b]pyrazinesand Pyrido[2,3-b]pyrazines

E. Günther, M. Gerlach, T. Schuster, 2011 .

New generation of anilino-substituted pyridopyrazine-urea derivatives show highly selective PI3K-inhibition

M. Teifel, E. Polymeropoulos, T. Schuster, 2007 .

Preparation of Novel 2,3,8-Trisubstituted Pyrido[3,4-b]pyrazines and Pyrido[2,3-b]pyrazines.

M. Gerlach, T. Schuster, E. Guenther, 2011 .

Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors

M. Teifel, E. Günther, M. Gerlach, 2016 .

Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.

M. Teifel, C. Logé, M. Le Borgne, 2014, Bioorganic & medicinal chemistry letters.

Discovery of 7‐Aryl‐Substituted (1,5‐Naphthyridin‐4‐yl)ureas as Aurora Kinase Inhibitors

M. Teifel, E. Günther, M. Gerlach, 2014, ChemMedChem.